Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Big pharma licensing deal volume grew 12% between 2012 and 2016, but according to a new report from Datamonitor Healthcare there were fewer deals and dollars attributed to partnerships in 2016.
Latest From Market Intelligence
Free article: What In Vivo has been saying about personalized medicine in this century.
Success rates are higher for clinical trials that incorporate selective pharmacogenomics and pharmacogenetics (PGX) biomarkers, according to data from Informa's Trialtrove. Given the challenges of designing and administering trials to secure regulatory approval in areas of unmet medical need, the data provide some basis for optimism in realizing the promise of targeted, personalized therapies that improve health outcomes for individual patients.
Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced in February 2017.
Servier signed a $1.7 billion immuno-oncology deal with Pieris; Johnson & Johnson paid $30 billion to acquire Actelion and its key pulmonary arterial hypertension assets. Device fundraising was significantly boosted by Verily's $800 million investment from Temasek.
Medtech companies raised $2.4 billion in the fourth quarter, the second-strongest of the year; Q4 device M&A deals totaled $9 billion in value, led by Allergan's $2.9 billion buy of Acelity's LifeCell division. Diagnostics financings finished out the year at $721 million, an increase over the previous quarter and 2016's second-highest quarter, but diagnostics M&A activity was the lowest of the year at $87 million, with only two completed acquisitions.
Free article: In Vivo's editors pick February's most significant deals, including Seattle Genetics' new ADC and Integra's big bid in neurosurgery.
You must sign in to use this functionality.
Please Sign In
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with active subscriptions will be able to access the full article. All other readers will be directed to the abstract and may purchase the article.